Hospital Pedro Hispano
7
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies
Role: collaborator
Evaluation of Inflammatory Markers in LARC Patients
Role: lead
Evaluation of cfDNA as a Marker of Response in Rectal Cancer
Role: lead
PIMA - Individualized Adherence Improvement Plan
Role: collaborator
Efficacy of PuraStat for the Prevention of Delayed Bleeding After Endoscopic Resection of Colorectal Lesions
Role: lead
Intensive Care Unit (ICU) Diaries as a Therapeutic Intervention for Post Traumatic Stress Disorder (PTSD) Following Critical Illness
Role: collaborator
Rosuvastatin Affecting Aortic Valve Endothelium
Role: lead
All 7 trials loaded